

2Q 2017 Update



SURGERY PARTNERS

Disclaimer

Forward-Looking Statements

This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this presentation other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential,” or the negative of those terms, and similar expressions and comparable terminology intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding the future financial position of Surgery Partners, Inc. and its subsidiaries (the “Company”), including financial targets, business strategy, plans and objectives for future operations and future operating results. These statements reflect the Company’s current views with respect to future events and are based on assumptions and subject to risks and uncertainties. These include, without limitation, risks and uncertainties related to the following: reductions in payments from, or inability to contract with, government healthcare programs managed care organizations and private third-party payors, failure to fully integrate the operations of Surgery Partners and Legacy Symbion, changes in the regulatory, economic and other conditions of the states where our surgical facilities are located, and other factors set forth under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for fiscal year 2015 (“10-K”) filed with the Securities and Exchange Commission (the “SEC”) as well as other information we file with the SEC. The Company cautions investors not to place considerable reliance on the forward-looking statements contained in this presentation. You should read the Company’s annual and quarterly reports, when available, and any and all other filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements contained in this presentation speak only as of the date of the presentation, and the Company undertakes no obligation to update or revise any forward-looking statements for any reason, except as required by law. The Company’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Data and Information Contained in this Presentation

This presentation also contains estimates, projections and other information concerning the Company’s industry, business and the market for its products and services, as well as data regarding market research, estimates and forecasts. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Certain data in this presentation was obtained from various external sources, and neither the Company nor its affiliates, advisers or representatives has verified such data with independent sources. Accordingly, neither the Company nor any of its affiliates, advisers or representatives makes any representations as to the accuracy or completeness of that data or to update such data after the date of this presentation. Such data involves risks and uncertainties and is subject to change based on various factors. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of the Company or the proposed offering.

Non-GAAP Financial Measures

This presentation contains certain non-GAAP financial measures, including EBITDA and Adjusted EBITDA. A “non-GAAP financial measure” is defined as a numerical measure of a company’s financial performance that excludes or includes amounts so as to be different than the most directly comparable measure calculated and presented in accordance with GAAP in the statements of income, balance sheets or statements of cash flow of the company. We present non-GAAP financial measures when we believe that the additional information is useful and meaningful to investors. Non-GAAP financial measures do not have any standardized meaning and are therefore unlikely to be comparable to similar measures presented by other companies. The presentation of non-GAAP financial measures is not intended to be a substitute for, and should not be considered in isolation from, the financial measures reported in accordance with GAAP. For additional information about our non-GAAP financial measures, and a reconciliation of certain non-GAAP financial measures to the comparable GAAP measures, see the Company’s 10-K, Quarterly Reports on Form 10-Q and other information we file with the SEC.

Company Overview

Surgery Partners Today

Healthcare Facilities

98

ASCs

5

Surgical Hospitals


59

Physician Practices

7


Urgent Care Facilities

National Network




Our Delivery Model

Solving for cost containment in the surgical continuum of care




Growth Opportunities in Action



Specialty Ancillary Specific Opportunities

Physician Practice Development — Opportunity Roadmap

Significant Runway to Replicate Success and Further Build Out Ancillary Offerings



Patient Entry Points



Freestanding
Emergency Department



Urgent Care Facilities



Primary Care

Creating a Win-Win-Win Value Proposition

A Physician-Centric Value Proposition Designed to Drive High Quality Patient Care in a Low Cost Setting

Patients

- Convenient, comfortable and cost-efficient settings
- Superior clinical outcomes and increasing patient satisfaction while reducing costs

Physicians

- Flexible approach to physician engagement: employment, partnership, affiliation
- Convenient and efficient surgical facilities
- Differentiated care delivery model enhancing care coordination, quality, outcomes

Payors

- Outpatient care at significantly lower cost than general acute care hospitals
- OIG estimates \$12bn Medicare savings shifting outpatient surgery to an ASC setting

NSH Acquisition

About National Surgical Healthcare

Highly Complementary and Strategic Asset



21 Surgical Facilities in 15 Markets



75% Musculoskeletal Procedure Mix



>1,200 Affiliated Physicians



Highly Contracted with Limited (~3%) Out of Network Exposure



Formerly Largest Privately Held Surgical Facility Platform in U.S.



Recognized Leader in Quality and Patient Satisfaction

New Long-Term World Class Shareholder



Bain Capital has agreed to acquire all outstanding Common Stock held by H.I.G. Capital and partner with Surgery Partners as the Company's largest shareholder

- ✓ Partnering with one of the world's leading multi-asset investment firms with approximately \$75 billion AUM
- ✓ One of the leading investors in the Healthcare sector
- ✓ Extensive experience across the healthcare value chain
- ✓ Strategic investment validating secular trends and dynamics in healthcare favoring low-cost providers



The New Surgery Partners

Natural Combination Expands on Outpatient Capabilities in Healthcare Delivery



Surgery Partners has agreed to acquire National Surgical Healthcare in a transaction valued at \$760M

- ✓ Largest standalone, independent surgical services company in the United States
- ✓ Expanded musculoskeletal capabilities in complex procedures as well as continuum of care breadth
- ✓ Payor-focused engagement strategy to address industry needs for cost of higher acuity cases
- ✓ Expected to be immediately accretive to Adjusted Cash EPS in 2018
- ✓ Shared “patient first” mentality among companies

124 surgical facilities across 32 states

~\$1.7 billion combined LTM revenue


~\$250 million combined LTM EBITDA

~\$20 million of identified synergies

Introducing The New Surgery Partners

National Network of Healthcare Facilities

- 106 ASCs
- 18 Surgical Hospitals
- 59 Physician Practices
- ✓ Facilities in 32 States
- ✓ >5,000 Affiliated Physicians
- ✓ Ancillary Services Infrastructure



● Existing Surgical Facilities
● NSH Facilities
● Physician Practices

Creating the Premier National Musculoskeletal Platform in the U.S.

2x

increase in hip revision procedures projected by 2026

\$7BN

annual Medicare spend on total joint procedures

100 million

Adults in the U.S. with chronic pain

~40%

Savings over HOPD setting

-
- ✓ First branded national musculoskeletal practice management company
 - ✓ Well positioned for opportunity to capture total-joint replacement procedures
 - ✓ Expanded network of total joint, orthopedic and spine capabilities
 - ✓ Front-end of industry trend toward moving high complexity cases to short stay settings
-




Diversified Pro Forma Business Mix

Delivers Stability, Growth, and Strong Margins

Payor Mix



Net Revenue by Payor



Specialty Mix

Volume

Net Revenue



■ Other ■ Musculoskeletal

Highly Experienced Management Team with Operational and Integration Track Record

Precedent Strategic M&A

 SURGERY PARTNERS




National
Surgical Healthcare


SYMBION
HEALTHCARE


NovaMed

Experienced Management Team



Track Record of Successful Integration of Transformational M&A



Differentiated Organic Growth Strategy



Operational Expertise Across Surgical Specialties and Related Services



Long History of Delivering Financial Results and Driving Shareholder Value

NSH Transaction Structure

Transaction Structure and Financing

Key Highlights

- ✓ New debt used to finance the acquisition of NSH and pay transaction fees
- ✓ Leverage neutral transaction
- ✓ Pro forma capital structure allows de-levering through growth
- ✓ Facilitates continued M&A activities while maintaining manageable leverage
- ✓ Jefferies providing committed financing

Financing and Structure

NSH Acquisition

- Secured Debt
 - New \$75 million Revolver
 - New 7-year \$1,290 million First Lien Term Loan (2024 maturity)
- Fixed Rate Debt
 - Existing \$400 million Senior Unsecured Notes remain in place (2021 maturity)
 - New 8-year \$370 million Senior Unsecured Notes (2025 maturity)
- Convertible Preferred Equity
 - New 5-year ~\$300 million Preferred Equity provided by Bain Capital
- **HIG Take-Out**
 - Bain will acquire outstanding stock of Surgery Partners held by HIG for cash

Track Record of Growth and Integration

 SURGERY PARTNERS



 SURGERY PARTNERS



 SURGERY PARTNERS



Year:	2011	2014	2016PF
Facilities:	49 ⁽²⁾	102 ⁽²⁾	124
Revenue:	\$260mm ⁽²⁾	\$871mm ⁽²⁾	~\$1.7bn

- Establishment of strong business foundation and services platform
- NovaMed added 37 surgical facilities and ancillary optical services to the platform
- Diversified geography and specialty mix
- Initial expansion into vertical integration

- Business diversification and services expansion focused on multi-specialty
- Launched diagnostic lab services (Logan Labs) in 2012
- Symbion added 55 surgical facilities and significantly increasing ancillary expansion targets
- IPO – October 2015

- Complementary expansion of multi-specialty capabilities
- Diversifies footprint and expands services to broaden breath of key service line offerings
- Provides significant opportunity to further adapt to changing dynamics in healthcare by further solving for cost and quality

Financial Update

Q2 2017 Performance Review

Financial Performance and Same-Facility Trends

- Q2 2017 Revenue of \$288.4 million and Adjusted EBITDA of \$37.1 million
 - 111,758 cases; \$2,580 revenue per case
- Achieved 2.0% same-facility revenue growth, driven by:
 - 0.4% same-facility case growth
 - 1.5% same-facility net revenue per case growth

Q2 MD&A


- Total company revenue for the second quarter of 2017 decreased 0.5% to \$288.4 million from \$289.7 million for the second quarter of 2016
 - Normalizing for the lapse of a an anesthesia contract with an unaffiliated provider, which was neutral to EBITDA but dilutive to revenue by approximately \$8.8 million, total company revenue increased by 2.7%
- The decline in Adjusted EBITDA versus prior year was largely driven by:
 - Similar to the industry, overall utilization was lower than forecast despite physician retention trends proving stronger than historical periods
 - Although there was an increase in higher acuity cases, an adverse payor mix hindered the overall benefit
 - Delays in new development while the previously announced National Surgical Healthcare transaction progresses to closing

New Development

- Completed three physician practice acquisition in existing markets during the YTD 2017 period for a combined purchase price of \$14.2 million
- Anticipate National Surgical Hospital transaction closing during the third quarter
 - Regulatory approval secured and financing finalized
- Continue to develop strong pipeline to foster continued growth and drive new physician relationships

Consistent Cash Flow Attributes


Capital Expenditures⁽¹⁾
(% of Revenue)



- Low historical maintenance capex as a percentage of net revenue of ~3%
- Growth capex has been strategically deployed to fund core surgical initiatives, new practice acquisitions, and internal development of ancillary operations

Normalized Free Cash Flow


Free Cash Flow⁽²⁾
(\$mm)



- Stable cash flows diversified across specialties, business lines, and geographies
- Ancillary services benefit consolidated margins
- History of disciplined cash flow management

Capital Structure

Leverage⁽¹⁾



Capitalization Table

(\$ in thousands)

Actual

Cash	\$	57.0
Indebtedness:		
Revolving Credit Facility	\$	91.0
1st Lien Term Loan	\$	927.3
Total Secured Debt	\$	1,018.3
Senior Unsecured Notes	\$	400.0
Subordinated Notes A	\$	1.0
Facility Level Debt	\$	67.6
Total Net Debt	\$	1,429.8

Concluding Remarks
